Abandoned by Amgen, Cy­to­ki­net­ics lands $50M upfront deal for Chinese rights to heart failure prospect

Cy­to­ki­net­ics has found another company that still sees a future for its heart failure prospect omecamtiv mecarbil. After losing partnerships with Amgen and Servier in quick succession, Cy­to­ki­net­ics has sold the Chinese rights to the candidate to Ji Xing Pharmaceuticals.